Clinical trials: Growth Hormone-Deficiency
Growth Hormone Deficiency
Study of TV-1106 in Growth Hormone-Deficient Adults
The primary objective of this study is to determine the efficacy of 6 months of treatment with TV-1106 compared with placebo on body fat composition.
- Trial name
- NCT02410343
- Testing
- TV-1106
- Where
- 33 sites in United States, Austria and 5 more
- Volunteers
- 14 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Adult Growth Hormone Deficiency
Metabolic Endocrinology and Growth Hormone in Adults
This is a multicentric, longitudinal, observational study with the prospective follow-up of Adult subjects with Growth Hormone Deficiency (AGHD) being treated with Saizen, every six months in the first year and then annually.
- Trial name
- MEGHA FRANCE (NCT01080755)
- Volunteers
- 90 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Growth Hormone Deficiency in Children
Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy
The aim of the study is to examine the suitability, the so-called validation, of a questionnaire, with which one can grasp the reasons why injections of growth hormones are omitted by patients ("non-adherence").
- Trial name
- NCT03672617
- Testing
- No treatment given
- Where
- Germany
- Volunteers
- 321 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children
The purpose of the multicenter, randomized, open-label, controlled phase II study is to determine whether pegylated recombinant human growth hormone is effective in the treatment of children with growth hormone deficiency.
- Trial name
- PD (NCT01342146)
- Testing
- pegylated Somatropin, Jintropin AQ
- Volunteers
- 101 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Disorder, Growth Hormone Deficiency in Children
A Single Dose Trial in Growth Hormone Deficient Children Investigating Safety, Pharmacokinetics and Pharmacodynamics of Long Acting Growth Hormone
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetics (the determination of the concentration of the administered medication in blood over time) and…
- Trial name
- NCT00936403
- Testing
- NNC126-0083, somatropin
- Where
- 21 sites in Belgium, Czechia and 8 more
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Disorder, Adult Growth Hormone Deficiency
First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects
This trial is conducted in Europe. The aim of this trial is to assess safety, tolerability, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of…
- Conditions
- Growth Hormone Disorder, Adult Growth Hormone Deficiency, Growth Hormone Deficiency in Children, Healthy
- Trial name
- NCT01514500
- Testing
- somapacitan
- Where
- Germany
- Volunteers
- 105 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Disorder, Growth Hormone Deficiency in Children
Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency
This trial is conducted in Asia. The aim of this trial is to evaluate the new liquid somatropin formulation in children with growth hormone deficiency.
- Conditions
- Growth Hormone Disorder, Growth Hormone Deficiency in Children, Genetic Disorder, Turner Syndrome
- Trial name
- NCT01563926
- Testing
- somatropin
- Where
- 6 sites in Israel
- Volunteers
- 168 people
- Sponsor
- Novo Nordisk A/S
Pediatric Growth Hormone Deficiency (PGHD)
A Bioequivalence Study of Two Different PEG-rhGH Preparations.
The purpose of this study is to investigate whether PEG-rhGH with new preparation is bioequivalent to PEG-rhGH with present preparation.
- Trial name
- NCT06331026
- Testing
- PEG-rhGH with new preparation (T), PEG-rhGH with present preparation (R)
- Where
- China
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Growth Hormone Deficiency
Transition Study: Growth Hormone Therapy In Partial Growth Hormone Deficient Adolescents
To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.
- Trial name
- TAUBER (NCT00156143)
- Testing
- Blood sample, Radiography
- Volunteers
- 90 people
- Sponsor
- Pfizer
Growth Hormone Deficiency
Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)
This study assesses the safety and tolerability of weekly TV-1106 compared to daily rhGH in adults with GHD who have previously been treated with rhGH.
- Trial name
- NCT02410356
- Testing
- TV-1106, dGH
- Where
- 50 sites in United States, Austria and 6 more
- Volunteers
- 34 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Growth Hormone Deficiency
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naïve to prior recombinant human growth hormone (rhGH)…
- Trial name
- NCT02311894
- Testing
- Somatropin
- Where
- 33 sites in United States
- Volunteers
- 82 people
- Sponsor
- Genentech, Inc.
Growth Hormone Deficiency
VRS-317 in Adult Subjects With Growth Hormone Deficiency
The purpose of this research study is to determine the safety and tolerability of up to five doses of VRS-317 in Adult Growth Hormone Deficient patients.
- Trial name
- NCT01359488
- Testing
- VRS-317
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Versartis Inc.
Growth Hormone Deficiency
Safety and Efficacy of SR-hGH (Sustained-release Human Growth Hormone, Declage Inj.)
As studies demonstrate, the administration of recombinant human GH (rhGH) in adults with GH deficiency has been known to improve metabolic impairment and quality of life.
- Trial name
- NCT01605331
- Testing
- sustained-release recombinant human GH (SR-rhGH)
- Volunteers
- 132 people
- Sponsor
- LG Life Sciences
Turner's Syndrome, Human Growth Hormone Deficiency
Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device
The purpose of this strictly observational, prospective, longitudinal study is to evaluate with sufficient precision the rate of overall treatment compliance from one year to 3 years of follow-up of the patients.
- Trial name
- ZOMAJET (NCT01306357)
- Testing
- Somatropin
- Where
- 17 sites in France
- Volunteers
- 87 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency
Observational Study of Somatropin Treatment in Children
GeNeSIS is an open-label, multinational, multicenter, observational study to evaluate the safety and effectiveness of Humatrope treatment.
- Conditions
- Growth Hormone (GH) Deficiency, Short Stature Homeobox Containing Gene (SHOX) Deficiency, SHOX Deficiency-related Disorder, Non-GH-deficient Growth Disorders
- Trial name
- GeNeSIS (NCT01088412)
- Testing
- Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)
- Volunteers
- 22,845 people
- Sponsor
- Eli Lilly and Company
Growth Hormone Deficiency
Sustained Release Formulation of Somatropin (rDNA Origin)for Injection
Annualised height velocity after 12/24 months treatment and HV SDS height velocity after 12/24 months treatment expressed as number of standard deviations difference from the mean population height velocity for the appropriate…
- Trial name
- NCT00600808
- Testing
- BPLG-003
- Volunteers
- 51 people
- Sponsor
- BioPartners GmbH
Growth Hormone Deficiency
Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
This is a multicenter, randomized, open-labeled, positive controlled phase 2\&3 combined study to evaluate the safety and efficacy of weekly Y-shape pegylated somatropin, compared to daily somatropin (Norditropin®), in…
- Trial name
- NCT04513171
- Testing
- Y-shape pegylated somatropin, Norditropin®, Norditropin
- Where
- China
- Volunteers
- 434 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Growth Hormone Disorder, Adult Growth Hormone Deficiency
A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
This trial is conducted in Europe. The aim of the trial is to investigate the safety, tolerability, availability and distribution in the body of once-weekly long-acting growth hormone (NNC0195-0092, somapacitan) compared to once…
- Trial name
- NCT01706783
- Testing
- somapacitan, Norditropin NordiFlex®
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Growth Hormone Deficiency
Online Surveillance of Treatment of Children With Growth Hormone Deficiency With ZOMACTON
The purpose of this study is to investigate long-term treatment with Zomacton® for pituitary short stature in children with insufficient growth hormone production and/or short stature caused by Turner syndrome.
- Trial name
- NCT01365351
- Testing
- Growth hormone
- Where
- 59 sites in Germany
- Volunteers
- 1,034 people
- Sponsor
- Ferring Pharmaceuticals
Growth Hormone Deficiency in Children
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).
- Trial name
- REAL4 (NCT03811535)
- Testing
- Somapacitan, Norditropin®
- Where
- 139 sites in United States, Algeria and 24 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S